Loading...
Despite the increasing array of antiretroviral agents approved for treatment of HIV infection, new drugs with unique mechanisms of action are needed for HIV-infected patients who are experiencing treatment failure. ACTG researchers (one of whom is employed by the drug manufacturer, and several of whom have received support from the company) now report results of a phase 2 trial of vicriviroc, an investigational agent that specifically binds the CCR5 chemokine receptor.
The double-blind, multicenter study involved 118 HIV-infected patients who were confirmed at their screening visits to have CCR5-tropic virus and who were experiencing virologic failure (viral load ≥5000 copies/mL) while receiving a ritonavir-containing regimen. Participants w…